Up regulated expression of fractalkine / CX 3 CL 1 and CX 3 CR 1 in patients with systemic sclerosis

Background: Fractalkine expressed on endothelial cells mediates activation and adhesion of leucocytes expressing its receptor, CX3CR1. Soluble fractalkine exhibits chemotactic activity for leucocytes expressing CX3CR1. Objective: To determine the role of fractalkine and its receptor in systemic sclerosis (SSc) by assessing their expression levels in patients with this disease. Methods: The expression of fractalkine and CX3CR1 in the skin and lung tissues was immunohistochemically examined. Circulating soluble fractalkine levels were examined by enzyme linked immunosorbent assay (ELISA). Blood samples from patients with SSc were stained for CX3CR1 with flow cytometric analysis. Results: CX3CR1 levels on peripheral monocytes/macrophages and T cells were found to be raised in patients with diffuse cutaneous SSc. The numbers of cells expressing CX3CR1, including monocytes/ macrophages, were increased in the lesional skin and lung tissues from patients with diffuse cutaneous SSc. Fractalkine was strongly expressed on endothelial cells in the affected skin and lung tissues. Soluble fractalkine levels were significantly raised in sera and were associated with raised erythrocyte sedimentation rates, digital ischaemia, and severity of pulmonary fibrosis. Conclusions: Up regulated expression of fractalkine and CX3CR1 cooperatively augments the recruitment of mononuclear cells expressing CX3CR1 into the affected tissue of SSc, leading to inflammation and vascular injury.

[1]  F. Luscinskas,et al.  Fractalkine Preferentially Mediates Arrest and Migration of CD16+ Monocytes , 2003, The Journal of experimental medicine.

[2]  K. Takehara.  Hypothesis: pathogenesis of systemic sclerosis. , 2003, The Journal of rheumatology.

[3]  P. Debré,et al.  Decreased Atherosclerotic Lesion Formation in CX3CR1/Apolipoprotein E Double Knockout Mice , 2003, Circulation.

[4]  I. Charo,et al.  Decreased atherosclerosis in CX3CR1-/- mice reveals a role for fractalkine in atherogenesis. , 2003, The Journal of clinical investigation.

[5]  N. Miyasaka,et al.  Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[6]  A. Koch,et al.  Selective lymphocyte chemokine receptor expression in the rheumatoid joint. , 2001, Arthritis and rheumatism.

[7]  D. Abraham,et al.  Transforming growth factor-&bgr; and connective tissue growth factor: key cytokines in scleroderma pathogenesis , 2001, Current opinion in rheumatology.

[8]  T. Imai,et al.  Fractalkine and vascular injury. , 2001, Trends in immunology.

[9]  A. Koch,et al.  Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. , 2001, The American journal of pathology.

[10]  A. Quyyumi,et al.  Association Between Polymorphism in the Chemokine Receptor CX3CR1 and Coronary Vascular Endothelial Dysfunction and Atherosclerosis , 2001, Circulation research.

[11]  P. Debré,et al.  Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. , 2001, Blood.

[12]  K. Matsushima,et al.  Upregulation of Fractalkine in Human Crescentic Glomerulonephritis , 2001, Nephron.

[13]  S. Sato,et al.  Delayed wound healing in the absence of intercellular adhesion molecule-1 or L-selectin expression. , 2000, The American journal of pathology.

[14]  A. Yamauchi,et al.  Fractalkine-Mediated Endothelial Cell Injury by NK Cells1 , 2000, The Journal of Immunology.

[15]  S. Sato.  Abnormalities of adhesion molecules and chemokines in scleroderma. , 1999, Current opinion in rheumatology.

[16]  Y. Xia,et al.  Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. , 1999, Kidney international.

[17]  D. Patel,et al.  Fractalkine and CX3CR1 Mediate a Novel Mechanism of Leukocyte Capture, Firm Adhesion, and Activation under Physiologic Flow , 1998, The Journal of experimental medicine.

[18]  T. Schall,et al.  Identification and Molecular Characterization of Fractalkine Receptor CX3CR1, which Mediates Both Leukocyte Migration and Adhesion , 1997, Cell.

[19]  J. Gutiérrez-Ramos,et al.  Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation , 1997, Nature.

[20]  M. Kahaleh,et al.  Mechanism of serum-mediated endothelial injury in scleroderma: identification of a granular enzyme in scleroderma skin and sera. , 1997, Clinical immunology and immunopathology.

[21]  Wei Wang,et al.  A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.

[22]  A. Miller,et al.  CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. , 1996, Immunity.

[23]  T. Tötterman,et al.  Phenotypic and functional activation of alveolar macrophages, T lymphocytes and NK cells in patients with systemic sclerosis and primary Sjögren's syndrome. , 1994, Annals of the rheumatic diseases.

[24]  H. Ihn,et al.  Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis. , 1994, Arthritis and rheumatism.

[25]  O. Ishikawa,et al.  Macrophage infiltration in the skin of patients with systemic sclerosis. , 1992, The Journal of rheumatology.

[26]  A. Freemont,et al.  Sequential dermal microvascular and perivascular changes in the development of scleroderma , 1992, The Journal of pathology.

[27]  N. Sepp,et al.  Expression of class II-MHC antigens in the dermis of patients with progressive systemic sclerosis. , 1991, Immunobiology.

[28]  K. Miller,et al.  Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. , 1990, The American journal of medicine.

[29]  T. Krieg,et al.  Localization of collagen mRNA in normal and scleroderma skin by in‐situ hybridization , 1988, European journal of clinical investigation.

[30]  T. Medsger,et al.  Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. , 1988, Arthritis and rheumatism.

[31]  T. Medsger,et al.  Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. , 1988, The Journal of rheumatology.

[32]  T. Whiteside,et al.  Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations. , 1984, Arthritis and rheumatism.

[33]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[34]  O. Yoshie,et al.  Defined by CX 3 CR 1 Expression Cytotoxic Effector Lymphocytes That Are + / Granzyme B + 1 in Trafficking of Perforin Dual Functions of Fractalkine / CX 3 C Ligand , 2002 .

[35]  P. Allavena,et al.  Fractalkine ( CX 3 CL 1 ) as an amplification circuit of polarized Th 1 responses , 2001 .

[36]  C. Tsou,et al.  Tumor Necrosis Factor- (cid:1) -converting Enzyme Mediates the Inducible Cleavage of Fractalkine* , 2001 .

[37]  金澤 伸雄.  Fractalkine and macrophage-derived chemokine: T cell attracting chemokines expressed in T cell area dendritic cells , 2000 .

[38]  S. Jimenez,et al.  Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. , 1995, Pathobiology : journal of immunopathology, molecular and cellular biology.

[39]  Richard W. Martin,et al.  Skin thickness score in systemic sclerosis , 1993 .